Impact of chemotherapy on patients with mismatch repair deficient advanced endometrial carcinomas—a meta-analysis
Menée à partir de données de 5 essais randomisés incluant 1 137 patientes atteintes d'un carcinome de l'endomètre de stade avancé ou récidivant, cette méta-analyse évalue l'efficacité, du point de vue du taux de réponse objective, de la survie sans progression et de la survie globale, d'une chimiothérapie à base de carboplatine en fonction du statut du système MMR (déficient ou non)
Introduction: Chemo-immunotherapy is standard of care for women with recurrent or advanced mismatch repair deficient (dMMR) endometrial carcinomas (EC). However, it is uncertain whether patients with dMMR advanced or recurrent EC derive less benefit from chemotherapy than those with mismatch repair proficient (pMMR) EC. Methods: We performed a meta-analysis of randomized controlled trials (RCTs) in advanced/recurrent EC to determine the difference in the benefit of chemotherapy in dMMR vs pMMR EC. Data on chemotherapy outcomes including objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) were retrieved. We pooled these data using the inverse variance method and examined subgroup difference by MMR status. We also compared differences in PFS and OS outcomes by creating individual patient data from the Kaplan-Meier curves of trial publications for sensitivity analyses. Results: A total of five RCTs with 1137 participants (dMMR, 26%; pMMR, 74%) were included. All participants were treated with carboplatin-based chemotherapy. There was no difference between the dMMR and pMMR subgroups for ORR (66.5% vs 64.0%, P = .20 for subgroup difference), PFS (HR 0.93, 95% CI 0.77-1.12, P = .44; median PFS 7.6 vs 9.5 months) or OS (HR 1.03, 95% CI 0.73-1.44, P = .88; median OS not reached vs 28.6 months). Conclusions: ORR, PFS and OS were similar among those with dMMR vs pMMR endometrial cancer treated with front-line, platinum-doublet chemotherapy in randomized clinical trials. These findings reinforce the importance of combining chemotherapy together with immune checkpoint inhibitors until the results of trials comparing immune checkpoint therapy alone with combination therapy are available.
JNCI Cancer Spectrum 2023